Authors,Title,Year,Source title,Volume,Issue,Art. No.,Page start,Page end,Page count,Cited by,DOI,Link,Affiliations,Authors with affiliations,Abstract,Author Keywords,Index Keywords,Molecular Sequence Numbers,Chemicals/CAS,Tradenames,Manufacturers,Funding Details,References,Correspondence Address,Editors,Sponsors,Publisher,Conference name,Conference date,Conference location,Conference code,ISSN,ISBN,CODEN,PubMed ID,Language of Original Document,Abbreviated Source Title,Document Type,Source,EID
"Fernandes A.P., Coelho E.A.F., Machado-Coelho G.L.L., Grimaldi G., Gazzinelli R.T.","Making an anti-amastigote vaccine for visceral leishmaniasis: Rational, update and perspectives",2012,"Current Opinion in Microbiology","15","4",,"476","485",,,10.1016/j.mib.2012.05.002,"http://www.scopus.com/inward/record.url?eid=2-s2.0-84865298084&partnerID=40&md5=5c573cb2692a4aa36eb66a4c9b92240f","Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil; Colégio Técnico, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil; Departamento de Ciências Médicas, Universidade Federal de Ouro Preto, Ouro Preto, MG, Brazil; Instituto Oswaldo Cruz, Centro de Pesquisa Gonçalo Moniz - FIOCRUZ/BA, Rua Waldemar Falcão, 121 (Candeal), Salvador, BA 40296-710, Brazil; Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil; Centro de Pesquisas René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil; University of Massachusetts Medical School, Worcester, MA, United States","Fernandes, A.P., Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil; Coelho, E.A.F., Colégio Técnico, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil; Machado-Coelho, G.L.L., Departamento de Ciências Médicas, Universidade Federal de Ouro Preto, Ouro Preto, MG, Brazil; Grimaldi, G., Instituto Oswaldo Cruz, Centro de Pesquisa Gonçalo Moniz - FIOCRUZ/BA, Rua Waldemar Falcão, 121 (Candeal), Salvador, BA 40296-710, Brazil; Gazzinelli, R.T., Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil, Centro de Pesquisas René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil, University of Massachusetts Medical School, Worcester, MA, United States","Visceral leishmaniasis is a major health problem in Latina America, as well as the Mediterranean region of Europe and Asia. We aimed to develop a vaccine against visceral leishmaniasis targeting the intracellular amastigotes, which is the parasite stage that persists throughout infections with Leishmania parasites. With this in mind, we identified an amastigote specific antigen (A2) that contains an immunogenic epitope for CD4+ T helper (Th) cells and multiple repetitive units encoding CD8+ cytotoxic T lymphocyte (CTL) epitopes. Vaccine formulations containing the recombinant A2 associated with saponin, alum and IL-12 or expressed by attenuated adenovirus were shown to be protective in mice, dogs and nonhuman-primates. We are currently identifying novel amastigote specific immunogenic proteins that could be aggregated to A2 to further improve the level of vaccine-induced cell-mediated immunity and protection against visceral leishmaniasis. © 2012 Elsevier Ltd.",,"adenovirus vector; aluminum potassium sulfate; amastigote antigen; interleukin 12; Leishmania vaccine; parasite antigen; saponin; unclassified drug; amastigote; CD4+ T lymphocyte; CD8+ T lymphocyte; cytotoxic T lymphocyte; dog; helper cell; human; immunogenicity; nonhuman; primate; review; visceral leishmaniasis; Animals; Antibodies, Protozoan; Antigens, Protozoan; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Dogs; Humans; Interleukin-12; Leishmania donovani; Leishmaniasis Vaccines; Leishmaniasis, Visceral; Macaca mulatta; Mice; Protozoan Proteins; Adenoviridae; Canis familiaris; Mus; Primates",,"aluminum potassium sulfate, 10043-67-1; interleukin 12, 138415-13-1; saponin, 8047-15-2; Antibodies, Protozoan; Antigens, Protozoan; Interleukin-12, 187348-17-0; Leishmaniasis Vaccines; Protozoan Proteins",,,,"Schriefer, A., Wilson, M.E., Carvalho, E.M., Recent developments leading toward a paradigm switch in the diagnostic and therapeutic approach to human leishmaniasis (2008) Curr Opin Infect Dis, 21, pp. 483-488; Grimaldi, G., Tesh, R.B., McMahon-Pratt, D., A review of the geographic distribution and epidemiology of leishmaniasis in the New World (1989) Am J Trop Med Hyg, 41, pp. 687-725; Berman, J., Visceral leishmaniasis in the New World & Africa (2006) Indian J Med Res, 123, pp. 289-294; Cupolillo, E., Aguiar Alves, F., Brahim, L.R., Naiff, M.F., Pereira, L.O., Oliveira-Neto, M.P., Falqueto, A., Grimaldi, G., Recent advances in the taxonomy of the New World leishmanial parasites (2001) Med Microbiol Immunol, 190, pp. 57-60; Mauricio, I.L., Stothard, J.R., Miles, M.A., Leishmania donovani complex: genotyping with the ribosomal internal transcribed spacer and the mini-exon (2004) Parasitology, 128, pp. 263-267; Hotez, P.J., Remme, J.H., Buss, P., Alleyne, G., Morel, C., Breman, J.G., Combating tropical infectious diseases: report of the disease control priorities in developing countries project (2004) Clin Infect Dis, 38, pp. 871-878; Desjeux, P., Leishmaniasis: current situation and new perspectives (2004) Comp Immunol Microbiol Infect Dis, 27, pp. 305-318; Croft, S., Olliaro, P., Leishmaniasis chemotherapy: challenges and opportunities (2011) Clin Microbiol Infect, 17, pp. 1478-1483; Sacks, D.L., Metacyclogenesis in Leishmania promastigotes (1989) Exp Parasitol, 69, pp. 100-103; Kaye, P., Scott, P., Leishmaniasis: complexity at the host-pathogen interface (2011) Nat Rev Microbiol, 9, pp. 604-615; Peters, N.C., Sacks, D.L., The impact of vector-mediated neutrophil recruitment on cutaneous leishmaniasis (2009) Cell Microbiol, 11, pp. 1290-1296; Reis, A.B., Giunchetti, R.C., Carrillo, E., Martins-Filho, O.A., Moreno, J., Immunity to Leishmania and the rational search for vaccines against canine leishmaniasis (2010) Trends Parasitol, 26, pp. 341-349; Ganguly, S., Das, N.K., Panja, M., Pal, S., Modak, D., Rahaman, M., Mallik, S., Goswami, R., Increased levels of interleukin-10 and IgG3 are hallmarks of Indian post-kala-azar dermal leishmaniasis (2008) J Infect Dis, 197, pp. 1762-1771; Saha, S., Mondal, S., Ravindran, R., Bhowmick, S., Modak, D., Mallick, S., Rahman, M., Guha, S.K., IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India (2007) J Immunol, 179, pp. 5592-5603; Nylen, S., Sacks, D., Interleukin-10 and the pathogenesis of human visceral leishmaniasis (2007) Trends Immunol, 28, pp. 378-384; Alves, C.F., de Amorim, I.F., Moura, E.P., Ribeiro, R.R., Michalick, M.S., Kalapothakis, E., Bruna-Romero, O., Melo, M.N., Expression of IFN-gamma, TNF-alpha, IL-10 and TGF-beta in lymph nodes associates with parasite load and clinical form of disease in dogs naturally infected with Leishmania (Leishmania) chagasi (2009) Vet Immunol Immunopathol, 128, pp. 349-358; Barbieri, C.L., Immunology of canine leishmaniasis (2006) Parasite Immunol, 28, pp. 329-337; Ghosh, M., Mandal, L., Maitra, S., Rakshit, S., Paul, K., Bagchi, J., Ganguly, D., Bandyopadhyay, S., Leishmania donovani infection of human myeloid dendritic cells leads to a Th1 response in CD4+ T cells from healthy donors and patients with kala-azar (2006) J Infect Dis, 194, pp. 294-301; Pepe, M., Altamura, M., Spinelli, R., Calvello, R., Saccia, M., Cavallo, P., Covelli, V., Brandonisio, O., Toll-like receptor-positive cells and recognition of pathogens: how human myeloid dendritic cells respond to in vitro infection with Leishmania infantum (2006) Curr Pharm Des, 12, pp. 4255-4262; Prajeeth, C.K., Haeberlein, S., Sebald, H., Schleicher, U., Bogdan, C., Leishmania-infected macrophages are targets of NK cell-derived cytokines but not of NK cell cytotoxicity (2011) Infect Immun, 79, pp. 2699-2708; Murray, H.W., Nathan, C.F., Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani (1999) J Exp Med, 189, pp. 741-746; Nylén, S., Maurya, R., Eidsmo, L., Manandhar, K.D., Sundar, S., Sacks, D., Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis (2007) J Exp Med, 204, pp. 805-817; Haeberlein, S., Sebald, H., Bogdan, C., Schleicher, U., IL-18, but not IL-15, contributes to the IL-12-dependent induction of NK-cell effector functions by Leishmania infantum in vivo (2010) Eur J Immunol, 40, pp. 1708-1717; Stern, J.J., Oca, M.J., Rubin, B.Y., Anderson, S., Murray, H., Role of L3T4+ and Lyt-2+ cells in experimental visceral leishmaniasis (1988) J Immunol, 141, pp. 3971-3977; Mc Elrath, M.J., Murray, H.W., Cohn, Z.A., The dynamics of granuloma formation in experimental visceral leishmaniasis (1988) J Exp Med, 167, pp. 1927-1937; Mary, C., Auriault, V., Faugere, B., Dessein, A.J., Control of Leishmania infantum infection is associated with CD8+ and IFN-gamma- and interleukin-5-producing CD4+ antigen-specific T cells (1999) Infect Immun, 67, pp. 5559-5566; Stager, S., Alexander, J., Kirby, A.C., Botto, M., Rooijen, N.V., Smith, D.F., Brombacher, F., Kaye, P.M., Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses (2003) Nat Med, 9, pp. 1287-1292; Basu, R., Bhaumik, S., Haldar, A.K., Naskar, K., De, T., Dana, S.K., Walden, P., Roy, S., Hybrid cell vaccination resolves Leishmania donovani infection by eliciting a strong CD8+ cytotoxic T-lymphocyte response with concomitant suppression of interleukin-10 (IL-10), but not IL-4 or IL-13 (2007) Infect Immun, 75, pp. 5956-5966; Polley, R., Stager, S., Prickett, S., Maroof, A., Zubairi, S., Smith, D.F., Kaye, P.M., Adoptive immunotherapy against experimental visceral leishmaniasis with CD8+ T cells requires the presence of cognate antigen (2006) Infect Immun, 74, pp. 773-776; Resende, D.M., Caetano, B.C., Dutra, M.S., Penido, M.L., Abrantes, C.F., Verly, R.M., Resende, J.M., Bruna-Romero, O., Epitope mapping and protective immunity elicited by adenovirus expressing the Leishmania amastigote specific A2 antigen: correlation with IFN-gamma and cytolytic activity by CD8+ T cells (2008) Vaccine, 26, pp. 4585-4593; Reis, A.B., Martins-Filho, O.A., Teixeira-Carvalho, A., Giunchetti, R.C., Carneiro, C.M., Mayrink, W., Tafuri, W.L., Corrêa-Oliveira, R., Systemic and compartmentalized immune response in canine visceral leishmaniasis (2009) Vet Immunol Immunopathol, 128, pp. 87-95; Smelt, S.C., Cotterell, S.E., Engwerda, C.R., Kaye, P.M., B cell-deficient mice are highly resistant to Leishmania donovani infection, but develop neutrophil-mediated tissue pathology (2000) J Immunol, 164, pp. 3681-3688; Thomas, B.N., Buxbaum, L.U., Fc gamma-RIII mediates immunoglobulin G-induced interleukin-10 and is required for chronic Leishmania mexicana lesions (2008) Infect Immun, 76, pp. 623-631; Miles, S.A., Conrad, S.M., Alves, R.G., Jeronimo, S.M., Mosser, D.M., A role for IgG immune complexes during infection with the intracellular pathogen Leishmania (2005) J Exp Med, 201, pp. 747-754; Maroof, A., Beattie, L., Zubairi, S., Svensson, M., Stager, S., Kaye, P.M., Post-transcriptional regulation of IL-10 gene expression allows natural killer cells to express immunoregulatory function (2008) Immunity, 29, pp. 295-305; Dumonteil, E., DNA vaccines against protozoan parasites: advances and challenges (2007) J Biomed Biotechnol, 2007, p. 90520; Kedzierski, L., Zhu, Y., Handman, E., Leishmania vaccines: progress and problems (2006) Parasitology, 133 (SUPPL.), pp. S87-S112; Gradoni, L., An update on antileishmanial vaccine candidates and prospects for a canine Leishmania vaccine (2001) Vet Parasitol, 100, pp. 87-103; Kedzierski, L., Sakthianandeswaren, A., Curtis, J.M., Andrews, P.C., Junk, P.C., Kedzierska, K., Leishmaniasis: current treatment and prospects for new drugs and vaccines (2009) Curr Med Chem, 16, pp. 599-614; Noazin, S., Modabber, F., Khamesipour, A., Smith, P.G., Moulton, L.H., Nasseri, K., Sharifi, I., Antunes, C.M., First generation leishmaniasis vaccines: a review of field efficacy trials (2008) Vaccine, 26, pp. 6759-6767; Palatnik-de-Sousa, C.B., Vaccines for leishmaniasis in the fore coming 25 years (2008) Vaccine, 26, pp. 1709-1724; Costa, C.H.N., Peters, N.C., Maruyama, S.R., Brito, E.C., Santos, I.K.F.M., Vaccines for the Leishmaniases: proposals for a research agenda. The Working Group on research priorities for development of leishmaniasis vaccines (2011) PLoS Negl Trop Dis, 5, pp. e943; Santos, W.R., de Lima, V.M., de Souza, E.P., Bernardo, R.R., Palatnik, M., Palatnik-de-Sousa, C.B., Saponins, IL-12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis (2002) Vaccine, 21, pp. 30-43; Reed, S.G., Coler, R.N., Campos-Neto, A., Development of a leishmaniasis vaccine: the importance of MPL (2003) Expert Rev Vaccines, 2, pp. 239-252; McMahon-Pratt, D., Rodriguez, D., Rodriguez, J.R., Zhang, Y., Manson, K., Bergman, C., Rivas, L., Ruddle, N.H., Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection (1993) Infect Immun, 61, pp. 3351-3359; Gabaglia, C.R., Pedersen, B., Hitt, M., Burdin, N., Sercarz, E.E., Graham, F.L., Gauldie, J., Braciak, T.A., A single intramuscular injection with an adenovirus-expressing IL-12 protects BALB/c mice against Leishmania major infection, while treatment with an IL-4-expressing vector increases disease susceptibility in B10.D2 mice (1999) J Immunol, 162, pp. 753-760; Darrah, P.A., Patel, D.T., de Luca, P.M., Lindsay, R.W., Davey, D.F., Flynn, B.J., Hoff, S.T., Morris, S.L., Multi-functional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major (2007) Nat Med, 13, pp. 843-850; Rhee, E.G., Mendez, S., Shah, J.A., Wu, C.Y., Kirman, J.R., Turon, T.N., Davey, D.F., Coler, R.N., Vaccination with heat-killed Leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against Leishmania major infection (2002) J Exp Med, 195, pp. 1565-1573; Stobie, L., Gurunathan, S., Prussin, C., Sacks, D.L., Glaichenhaus, N., Wu, C.Y., Seder, R.A., The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge (2000) Proc Natl Acad Sci USA, 97, pp. 8427-8432; Iwasaki, A., Medzhitov, R., Toll-like receptor control of the adaptive immune responses (2004) Nat Immunol, 5, pp. 987-995; Zhang, W.W., Matlashewski, G., Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice (2008) Infect Immun, 76, pp. 3777-3783; Dondji, B., Perez-Jimenez, E., Goldsmith-Pestana, K., Esteban, M., McMahon-Pratt, D., Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis (2005) Infect Immun, 73, pp. 5286-5289; Ramiro, M.J., Zarate, J.J., Hanke, T., Rodriguez, D., Rodriguez, J.R., Esteban, M., Lucientes, J., Larraga, V., Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK (2003) Vaccine, 21, pp. 2474-2484; Ramos, I., Alonso, A., Marcen, J.M., Peris, A., Castillo, J.A., Colmenares, M., Larraga, V., Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response (2008) Vaccine, 26, pp. 333-344; Carson, C., Antoniou, M., Ruiz-Arguello, M.B., Alcami, A., Christodoulou, V., Messaritakis, I., Quinnell, R.J., Courtenay, O., A prime/boost DNA/modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis (2009) Vaccine, 27, pp. 1080-1086; Wenzel, U.A., Bank, E., Florian, C., Förster, S., Zimara, N., Steinacker, J., Klinger, M., Van Zandbergen, G., Leishmania major parasite stage-dependent host cell invasion and immune evasion (2012) FASEB J, 26, pp. 29-39; Peters, N.C., Kimblin, N., Secundino, N., Kamhawi, S., Lawyer, P., Sacks, D.L., Vector transmission of Leishmania abrogates vaccine-induced protective immunity (2009) PLoS Pathog, 5, pp. e1000484; RohouŠová, I., Hostomská, J., Vlková, M., Kobets, T., Lipoldová, M., Volf, P., The protective effect against Leishmania infection conferred by sand fly bites is limited to short-term exposure (2011) Int J Parasitol, 41, pp. 481-485; Titus, R.G., Gueiros-Filho, F.J., de Freitas, L.A., Beverley, S.M., Development of a safe live Leishmania vaccine line by gene replacement (1995) Proc Natl Acad Sci USA, 92, pp. 10267-10271; Silvestre, R., Cordeiro-da-Silva, A., Ouaissi, A., Live attenuated Leishmania vaccines: a potential strategic alternative (2008) Arch Immunol Ther Exp (Warsz), 56, pp. 123-126; Kumari, S., Samant, M., Khare, P., Misra, P., Dutta, S., Kolli, B.K., Sharma, S., Dube, A., Photodynamic vaccination of hamsters with inducible suicidal mutants of Leishmania amazonensis elicits immunity against visceral leishmaniasis (2009) Eur J Immunol, 39, pp. 178-191; Charest, H., Matlashewski, G., Developmental gene expression in Leishmania donovani: differential cloning and analysis of an amastigote-stage-specific gene (1994) Mol Cell Biol, 14, pp. 2975-2984; Zhang, W.W., Charest, H., Ghedin, E., Matlashewski, G., Identification and over-expression of the A2 amastigote-specific protein in Leishmania donovani (1996) Mol Biochem Parasitol, 78, pp. 79-90; Ghedin, E., Zhang, W.W., Charest, H., Sundar, S., Kenney, R.T., Matlashewski, G., Antibody response against a Leishmania donovani amastigote-stage-specific protein in patients with visceral leishmaniasis (1997) Clin Diagn Lab Immunol, 4, pp. 530-535; McCall, L.I., Matlashewski, G., Localization and induction of the A2 virulence factor in Leishmania: evidence that A2 is a stress response protein (2010) Mol Microbiol, 77, pp. 518-530; Zhang, W.W., Matlashewski, G., Loss of virulence in Leishmania donovani deficient in an amastigote-specific protein, A2 (1997) Proc Natl Acad Sci USA, 94, pp. 8807-8811; Zhang, W.W., Matlashewski, G., Characterization of the A2-A2rel gene cluster in Leishmania donovani: involvement of A2 in visceralization during infection (2001) Mol Microbiol, 39, pp. 935-948; Mizbani, A., Taslimi, Y., Zahedifard, F., Taheri, T., Rafati, S., Effect of A2 gene on infectivity of the nonpathogenic parasite Leishmania tarentolae (2011) Parasitol Res, 109, pp. 793-799; Zhang, W.W., Mendez, S., Ghosh, A., Myler, P., Ivens, A., Clos, J., Sacks, D.L., Matlashewski, G., Comparison of the A2 gene locus in Leishmania donovani and Leishmania major and its control over cutaneous infection (2003) J Biol Chem, 278, pp. 35508-35515; Carvalho, F.A., Charest, H., Tavares, C.A., Matlashewski, G., Valente, E.P., Rabello, A., Gazzinelli, R.T., Fernandes, A.P., Diagnosis of American Visceral Leishmaniasis in humans and dogs using the recombinant Leishmania donovani A2 antigen (2002) Diagn Microbiol Infect Dis, 43, pp. 289-295; Porrozzi, R., da Costa, M.V.S., Teva, A., Falqueto, A., Ferreira, A.L., dos Santos, C.D., Fernandes, A.P., Grimaldi, G., Comparative evaluation of enzime-linked immunosorbent assays based on crude and recombinant leishmanial antigens for serodiagnosis of symptomatic and asymptomatic Leishmania infantum visceral infections in dogs (2007) Clin Vaccine Immunol, 14, pp. 544-548; Martins, D.R., Jeronimo, S.M., Donelson, J.E., Wilson, M.E., Leishmania chagasi T-cell antigens identified through a double library screen (2006) Infect Immun, 74, pp. 6940-6948; Ghosh, A., Zhang, W.W., Matlashewski, G., Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infection (2001) Vaccine, 20, pp. 59-66; Coelho, E.A., Tavares, C.A.P., Carvalho, F.A.A., Chaves, K.F., Teixeira, K.N., Rodrigues, R.C., Charest, H., Fernandes, A.P., Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection (2003) Infect Immun, 71, pp. 3988-3994; Ghosh, A., Labrecque, S., Matlashewski, G., Protection against Leishmania donovani infection by DNA vaccination: increased DNA vaccination efficiency through inhibiting the cellular p53 response (2001) Vaccine, 19, pp. 3169-3178; Zanin, F.H.C., Coelho, E.A.F., Tavares, C.A.P., Marques-da-Silva, E., Costa, M.M., Resende, S.A., Gazzinelli, R.T., Fernandes, A.P., Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infection (2007) Microbes Infect, 9, pp. 1070-1077; Yam, K.K., Hugentobler, F., Pouliot, P., Stern, A.M., Lalande, J.D., Matlashewski, G., Olivier, M., Cousineau, B., Generation and evaluation of A2-expressing Lactococcus lactis live vaccines against Leishmania donovani in BALB/c mice (2011) J Med Microbiol, 60, pp. 1248-1260; Mizbani, A., Taheri, T., Zahedifard, F., Taslimi, Y., Azizi, H., Azadmanesh, K., Papadopoulou, B., Rafati, S., Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis (2009) Vaccine, 28, pp. 53-62; Fernandes, A.P., Costa, M.M., Coelho, E.A., Michalick, M.S., de Freitas, E., Melo, M.N., Tafuri, W., Abrantes, C., Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein (2008) Vaccine, 26, pp. 5888-5895; Costa, M.M., Andrade, H.M., Bartholomeu, D.C., Freitas, L.M., Pires, S.F., Chapeaurouge, A.D., Perales, J., Melo, M.N., Analysis of Leishmania chagasi by 2-D difference gel eletrophoresis (2-D DIGE) and immunoproteomic: identification of novel candidate antigens for diagnostic tests and vaccine (2011) J Proteome Res, 10, pp. 2172-2184; Coelho, V.T.S., Oliveira, J.S., Valadares, D.G., Chávez-Fumagalli, M.A., Duarte, M.C., Lage, P.S., Soto, M., Fernandes, A.P., Identification of proteins in promastigote and amastigote-like stages of Leishmania using an immunoproteomic approach (2011) PLoS Negl Trop Dis, 6, p. 1430","Fernandes, A.P.; Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil; email: anapaula.fernandes@pq.cnpq.br",,,,,,,,13695274,,COMIF,22698479,"English","Curr. Opin. Microbiol.",Review,Scopus,2-s2.0-84865298084
